Chronic graft-versus-host disease.

By J. Bolaños-Meade, G. Vogelsang. Current pharmaceutical design, 2008

609 citations recorded by the source corpus.

Subfields: Hematology

View Paper: https://www.semanticscholar.org/paper/c572df2b6402f943320ab32f98a754d2b613c2a4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Jagasia
2. H. Greinix
3. D. Weisdorf
4. M. Ende
5. M. Arora
6. M. Flowers
7. Kirsten M. Williams
8. F. I. Ende

Citations in the corpus

• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report (2005, background): “Hyperbilirubinemia and small intestinal/colonic involvement are known risk factors for increased mortality in chronic GVHD patients (reviewed in [2]) [7,25,26].”
• Hematopoietic stem-cell transplantation. (2006, background): “Major risk factors for the development of cGvHD include prior aGvHD, a higher degree of HLA mismatch, older age of donor or host, subacute GvHD on skin biopsy, or buccal mucosal biopsy, CMV seropositivity (donor and recipient), and total body irradiation-containing regimens.(83,84,86,87) Predictive ”